About Ulysses Pharmaceuticals
Ulysses Pharmaceuticals is dedicated to the discovery and development of safe antimicrobial agents for the treatment of severe and recurrent infections occurring in humans. The Company intends to become an industry leader in the antiinfective field through the development of new antibiotics including some acting as Trojan Horses that take advantage of essential microbial transport systems to specifically enter targeted pathogens. Ulysses concentrates on the development of advanced hit and lead compounds with promising features and characteristics that are indicative of potent antibacterial agents with potential for strong market penetration.
Missing: Ulysses Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Ulysses Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Ulysses Pharmaceuticals Frequently Asked Questions (FAQ)
Where is Ulysses Pharmaceuticals's headquarters?
Ulysses Pharmaceuticals's headquarters is located at 238, ch. D'Orford-sur-le-lac Eastman, Sherbrooke.
What is Ulysses Pharmaceuticals's latest funding round?
Ulysses Pharmaceuticals's latest funding round is Other Investors.
Who are the investors of Ulysses Pharmaceuticals?
Investors of Ulysses Pharmaceuticals include BDC Venture Capital.
Who are Ulysses Pharmaceuticals's competitors?
Competitors of Ulysses Pharmaceuticals include Aquinox Pharmaceuticals, Tetraphase Pharmaceuticals, Actinobac Biomed, Eiger BioPharmaceuticals, CoLucid Pharmaceuticals and 13 more.
Compare Ulysses Pharmaceuticals to Competitors
Chemopreventia focuses on the development of cancer preventive drugs and works on the mechanism of action of retinoids and other chemopreventive agents in the control of epithelial cancers. The company also focuses on the protein receptors that mediate the action of chemopreventive agents.
Affinium Pharmaceuticals is a specialty pharmaceutical company developing a class of antibiotics that target the bacterial fatty acid synthesis (FASII) pathway. AFN-1252, the company's lead clinical compound, is a highly-potent, small molecule antibiotic for both oral and IV treatment of staphylococcal infections, including MRSA and all other drug-resistant strains.
Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.
Locus Pharmaceuticals is a privately held pharmaceutical company focused on developing small molecule therapeutic drugs to address unmet medical needs. The company's core technology is a fragment-based, computational approach, which Locus has combinated with highly integrated medicinal chemistry, crystallography and biology capabilities to create a unique drug design and development platform.
NeurAxon is discovering and developing next generation pain therapeutics focused on the inhibition of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization. NeurAxon's lead product candidate, NXN-188, is a first-in-class, dual-action small molecule incorporating both nNOS inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.
Tacere Therapeutics, Inc. specializes in the development of both traditional and therapeutics for the treatment of Hepatitis C (HCV). Combining expertise in small molecules, gene medicine, and RNA interference (RNAi), Tacere possesses skill in the screening and identification of both pharmaceutical and biological agents for the treatment of this major unmet medical need.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.